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1. INTRODUCTION 
  The complexity of daily life in modern society frequently leads to varying 
degrees of anxiety. Anxiety disorders have been found to be associated with chronic 
pain among hospitalized patients in both developed and developing countries.
1 
Anxiety disorders, the most prevalent psychiatric illnesses in the general community, 
are present in 15-20% of hospitalized patients. 
  Anxiety it is an emotional state, unpleasant in nature, associated with 
uneasiness, discomfort and concern or fear about some defined or undefined future 
thread. Some degree of anxiety is a part of normal life. Treatment is needed when it 
disproportionate to the situation and excessive.
2
 
  Anxiety disorders occur in approximately 30% of mood cases
3
. Lifetime 
prevalence rates for total anxiety disorders are 16.6%. Women are more likely to 
suffer from anxiety disorders because women experience a wider range of life events 
including events happening to their close as well as distant relatives and friends, in 
comparison to men, who react to events limited to themselves or close family 
members.
4
 Anxiety disorders are common during the perinatal period, with reported 
rates of obsessive‐ compulsive disorder and generalized anxiety disorder being higher 
in postpartum women than in the general population.
[5]
 Social anxiety disorder (SAD) 
is among the most common of all psychiatric disorders with lifetime prevalence 
estimates ranging from 7% to 13%.
3
 Co‐morbidity of anxiety and depression is highly 
prevalent. About 47.5% patients of major depressive disorder also meet criteria for 
anxiety disorders, whereas 26.1% patients of anxiety disorders meet criteria for major 
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depressive disorder too.
6
 About 8% of patients consulting primary care professionals 
have generalized anxiety disorder. Initial manifestations of anxiety appear at age of 
20‐35 years and there is predominance in women. Panic disorder commonly coexists 
with essential hypertension and the postural tachycardia syndrome.
7 
   Anxiety states are controlled by both inhibitory and facilitatory mechanisms 
that either counter or favor anxiety states. These neurochemical and neuropeptide 
systems have been shown to have effects on distinct cortical and sub cortical brain 
areas that are relevant to the mediation of the symptoms associated with anxiety 
disorders.
8
 Regional brain networks involved in such stress, anxiety, and anxious 
behaviors may be appropriate targets for actions of anxiolytics. Drug development in 
this direction also aims to generate new pharmacological agents with action at specific 
neurotransmitters and neuropeptides, their reuptake and metabolism. The ultimate 
objective is to develop substances that are as effective as benzodiazepines, which 
have been the traditional treatment for anxiety for over 40 years. This search has led 
to development of unconventional agents, which are either partial 
benzodiazepine‐GABA receptor agonists or target specific subunits of the GABA 
receptor or manipulate GABA levels, agents that affect the serotonin and nor-
epinephrine systems, antagonists of neurotransmitter systems such as 
corticotropin‐releasing factor and Substance P, agents that decrease glutamate 
neurotransmission, such as metabotropic glutamate receptor agonists, stimulation of 
neurotrophic factors, such as brain‐derived neurotrophic factor, which appears to 
enhance neurogenesis.
9 
A broad range of pharmacologic agents are available to treat anxiety disorders 
namely Selective Serotonin Reuptake Inhibitors, Selective Nor epinephrine Reuptake 
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Inhibitors, Tricyclic Antidepressants, MonoAmineOxidase Inhibitors, Buspirone, 
Benzodiazepines, Hydroxyzine, Antipsychotic, Anticonvulsants and Adrenergic 
agents.
2
 
 Sleep disturbance is amongst the most frequent health complaints, which the 
Physicians encounter. It is popularly known as insomnia. It is defined as persistent 
difficulty in falling or staying asleep.10 Sleep is a physiologic recuperative state that 
can be disturbed by many factors such as illness, stress and noise. Chronic sleep 
disorder leads to some health repercussions such as slower reactions, poor 
memorizing, emotional disturbances, and changes in the immune response.11, 12 
Today, sleep disorders have a relatively high prevalence and are a growing public 
health problem. It is estimated that more than 27% of people worldwide suffer from 
sleep disorders with difficulty in initiating or maintaining sleep. In addition, it is 
expected that by the middle of the 21 century, about 31% of all people will be chronic 
and frequent users of sleep medications.
12, 14 
Currently, the most widely used 
medications for sleep disorders are the benzodiazepines.  
      However, the regular uses of the above synthetic drugs results in unpleasant 
side effects such as drug dependence, tolerance, rebound insomnia, amnesia, 
psychomotor impairment and potentiating of other central depressant drugs.
15
 Thus, 
researchers, are now exploring natural resources to find out more efficacious and safer 
drugs. 
  Traditional and folk remedies have provided us with important drugs in the 
treatment of many diseases and are being increasingly subjected to scientific study. 
       In recent years, traditional system of medicine has become a topic of global 
importance. Many of the plant species that provide medicinal herbs have been 
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scientifically evaluated for their possible medicinal applications.
16
 Even today, this 
area holds much more hidden treasure as almost 80% of human population in 
developing countries is dependent on plant resources for healthcare.
17
 Herbal 
medicines offer conventional treatments, providing safe and well-tolerated remedies 
for chronic illness which typically resulted from the combinations of secondary plant 
metabolites that are synthesized and deposited in specific parts or in all part of the 
plant. Since, many of the synthetic drugs cause various side effects, drugs synthesized 
from the higher plants continue to occupy an important niche in modern medicine and 
play an important role in modern medicine and introduction of new therapeutic 
agents.  
       These are many medicinal plants that have stimulating or calming effects on 
the central nervous system, and the plant kingdom provides hundreds of CNS active 
substances covering the whole spectrum of activity such as psychoanaleptic, 
psycholeptic and psychodysleptic (hallucinogenic) effects.
18, 19
 There is tremendous 
hope that drugs of plant origin will have significantly lesser side effects than that 
observed with synthetic drugs while having comparable efficacy.
20
 
        Some of the plants that have been tested had shown to posses antianxiety & 
sedative effect includes Matricaria recutita, Tilia europaea, valeriana officeinalis, 
passiflora caeulea, Valeriana officeinalis, Stachys lavanaulifolia,calotropis 
gigantean, Passiflora caeulea, pachyrrhizus erosus
 ,
Salvia reterana and Nepeta 
cataria
 21 etc… 
 One such search for plant with antianxiety and sedative effect Amomum 
subulatum was chosen for the study on the basis of its traditional use. Amomum 
subulatum is commonly known as large cardamom .Amomum subulatum seed is used 
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traditionally in stomachis, indigestion, abdominal pain and rectal disease. The seeds 
of the plants have good taste and are a tonic for liver and heart. They are astringent to 
the bowels, appetizing, hypnotic and aid digestion.  The current study was carried out 
in an attempt to investigate potential sedative and anxiolytic effect of various extracts 
of Amomum subulatum seeds in  mice using elevated plus maze(EPM) and 
spontaneous motor activity tests. 
 
 
 
 
 
 
 
 
 
                                                                                    Aim & Objective 
 
Institute of Pharmacology, MMC. Page 6 
 
 
                                  2. AIM AND OBJECTIVE 
AIM 
The aim of the present study is to evaluate the anti-anxiety and sedative effects 
of various extracts of Amomum subulatum seeds in Swiss albino mice. 
OBJECTIVE 
 To analyse the phytochemical profile of various extracts of Amomum 
subulatum seeds. 
 In-vitro antioxidant activity is used to determine the presence of active 
constituents in various extracts. 
 In-vivo spontaneous locomotor activity is to be done by actophotometer& 
open field for sedative activity. 
 In-vivo antianxiety activity is to be done by elevated plus maze method. 
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                  3. REVIEW OF LITERATURE 
 
3.1 ANXIETY 
Anxiety is a state of excessive fear and is characterized by motor sympathetic 
hyperactivity, apprehension and vigilance syndromes. The most common observation 
is an acute stress response characterized by a state of abnormal or exaggerated arousal 
or fear. Generally, anxiety is an adaptive response to supposedly dangerous stimuli, 
which may perturb homeostasis. However, when it become disproportional in 
intensity, chronic and/or irreversible, or not genuine, it manifest as debilitating 
anxious state presenting itself in form of phobia, panic attacks, post‐traumatic stress 
disorder, social anxiety disorder or generalized anxiety disorder.
8 
3.1.1 Symptoms 22 
Common anxiety signs and symptoms include: 
 Feeling nervous, restless or tense 
 Having a sense of impending danger, panic or doom 
 Having an increased heart rate 
 Breathing rapidly (hyperventilation) 
 Sweating 
 Trembling 
 Feeling weak or tired 
 Trouble concentrating or thinking about anything other than the present 
worry 
 Having trouble sleeping 
 Experiencing gastrointestinal (GI) problems 
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 Having difficulty controlling worry 
 Having the urge to avoid things that trigger anxiety 
3.1.2 Etiology of Anxiety Disorders 23 
Table 1: Etiology of anxiety disorders 
     Biological factor    Psychological factor       Social causes  
Heredity Personality traits Adverse Life Experiences 
Neurotransmitter 
imbalance 
Low self-esteem Lack of social support 
Illness Cognitive dissonance Work stress 
Medications Negative emotions Lack of social skills 
Nutritional factors Inter and/or intra-personal 
conflicts 
Conflict of societal norms 
 Perception of situational 
factors 
Natural calamities 
 
Psychological factors 
Anxiety can result when a combination of increased internal and external 
stresses overwhelm one’s normal coping abilities or when one’s ability to cope 
normally is lessened for some reason.  
The psychological factors are summarized below: 
Psychodynamic: When internal competing mental processes, instincts and impulses 
conflict, causing distress.  
Behavioral: Anxiety is a maladaptive learned response to specific past experiences 
and situations that become generalized to future similar situations. 
                                                                                             Review Of Literature 
 
Institute of Pharmacology, MMC. Page 9 
 
Spiritual: When people experience a profound, unquenchable emptiness and 
nothingness to their lives, often leading to distress concerning their mortality and 
eventual death. 
Social factors 
Life experiences like death in the family, divorce, job loss, financial loss, 
accident or major illness affect a person’s attitude and response to life situations. 
Long term exposure to abuse, violence, terrorism and poverty may affect an 
individual’s susceptibility to anxiety disorders. 
Oxidative stress 
High O2 consumption, modest antioxidant defenses and a lipid-rich 
constitution make the brain highly vulnerable to redox imbalances. Oxidative damage 
in the brain causes nervous system impairment. Recently, oxidative stress has also 
been implicated in depression, anxiety disorders and high anxiety levels.
24 
Anxiety due to a general medical condition:
 22 
For some people, anxiety may be linked to an underlying health issue. In some 
cases, anxiety signs and symptoms are the first indicators of a medical illness. If your 
doctor suspects your anxiety may have a medical cause, he or she may order tests to 
look for signs of a problem. 
Examples of medical problems that can be linked to anxiety include: 
 Heart disease 
 Diabetes 
 Thyroid problems, such as hyperthyroidism 
 Respiratory disorders, such as chronic obstructive pulmonary disease 
(COPD) and asthma 
 Drug abuse or withdrawal 
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 Withdrawal from alcohol, anti-anxiety medications (benzodiazepines) or 
other medications 
 Chronic pain or irritable bowel syndrome 
 Rare tumors that produce certain "fight-or-flight" hormones 
3.1.3 Risk factors 22 
These factors may increase the risk of developing an anxiety disorder:  
 Trauma. Children who endured abuse or trauma or witnessed traumatic 
events are at higher risk of developing an anxiety disorder at some point in 
life. Adults who experience a traumatic event also can develop anxiety 
disorders. 
 Stress due to an illness. Having a health condition or serious illness can 
cause significant worry about issues such as the treatment and the future. 
 Stress buildup. A big event or a buildup of smaller stressful life situations 
may trigger excessive anxiety — for example, a death in the family, work 
stress or ongoing worry about finances. 
 Personality. People with certain personality types are more prone to 
anxiety disorders than others are. 
 Other mental health disorders. People with other mental health 
disorders, such as depression, often also have an anxiety disorder.  
 Having blood relatives with an anxiety disorder. Anxiety disorders can 
run in families. 
 Drugs or alcohol. Drug or alcohol use or abuse or withdrawal can cause 
or worsen anxiety 
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3.1.4 Complications 22 
Having an anxiety disorder does more than make you worry. It can also lead to, or 
worsen, other mental and physical conditions, such as: 
 Depression (which often occurs with an anxiety disorder) or other mental 
health disorders 
 Substance abuse 
 Trouble sleeping (insomnia) 
 Digestive or bowel problems 
 Headaches and chronic pain 
 Social isolation 
 Problems functioning at school or work 
 Poor quality of life 
 Suicide 
3.1.5 Diagnostic and Statistical Manual of Mental Disorders, 4
th
 
edition text revision (DSM IV) Anxiety Disorder include 
1. Generalized anxiety disorder 
2. Social anxiety disorder 
3. Agoraphobia without panic 
4. Obsessive compulsive disorder(OCD) 
5. Acute stress disorder 
6. Panic disorder with or without agoraphobia 
7. Post-traumatic stress disorder 
8. Anxiety disorder otherwise specified 
9. Specific phobia 
10. anxious depression 
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11. substance induced anxiety disorder 
12. selective mutism 
DSM-IV also list anxiety occurring as an adjustment disorder, or secondary to 
substance abuse or a general medical condition.
25 
Key phenomenological features of major anxiety disorders as defined by DSM-
V-TM
 23, 26- 28 
I. Separation anxiety disorder 
  The individual with separation anxiety disorder is fearful or anxious about 
separation from attachment figures to a degree that is developmentally inappropriate. 
There is persistent fear or anxiety about harm coming to attachment figures and 
events that could lead to loss of or separation from attachment figures and reluctance 
to go away from attachment figures, as well as nightmares and physical symptoms of 
distress. Although the symptoms often develop in childhood, they can be expressed 
throughout adulthood as well. 
II. Selective mutism 
Selective mutism is characterized by a consistent failure to speak in social 
situations in which there is an expectation to speak (e.g., school) even though the 
individual speaks in other situations. The failure to speak has significant 
consequences on achievement in academic or occupational settings or otherwise 
interferes with normal social communication. 
III. Specific phobia  
 Individuals with specific phobia are fearful or anxious about or avoidant of 
circumscribed objects or situations. A specific cognitive ideation is not featured in 
this disorder, as it is in other anxiety disorders. The fear, anxiety, or avoidance is 
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almost always immediately induced by the phobic situation, to a degree that is 
persistent and out of proportion to the actual risk posed.  
There are various types of specific phobias:  
Animal (e.g. snakes and dogs) 
Natural environment (e.g. height) 
Blood-injection-injury 
Situational (e.g. flying) 
IV. Social anxiety disorder 
In social anxiety disorder (social phobia), the individual is fearful or anxious 
about or avoidant of social interactions and situations that involve the possibility of 
being scrutinized. These include social interactions such as meeting unfamiliar 
people, situations in which the individual may be observed eating or drinking, and 
situations in which the individual performs in front of others. The cognitive ideation is 
of being negatively evaluated by others, by being embarrassed, humiliated, or 
rejected, or offending others. 
V. Panic disorder 
Recurrent unexpected panic attacks characterized by four or more of the following 
 Sweating and shaking 
 Tremor 
 Shortness of breath 
 Hyperventilation 
 A choking sensation  
 Chest discomfort and palpitation 
 Nausea 
 Dyspepsia 
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 Paresthesia 
 Derealisation and depersonalization,  
 Sense of impending doom or death 
VI. Agoraphobia 
Individuals with agoraphobia are fearful and anxious about two or more of the 
following situations: using public transportation; being in open spaces; being in 
enclosed places; standing in line or being in a crowd; or being outside of the home 
alone in other situations. The individual fears these situations because of thoughts that 
escape might be difficult or help might not be available in the event of developing 
panic-like symptoms or other incapacitating or embarrassing symptoms. These 
situations almost always induce fear or anxiety and are often avoided and require the 
presence of a companion. 
VII. Generalized anxiety disorder 
The key features of generalized anxiety disorder are persistent and excessive 
anxiety and worry about various domains, including work and school performance, 
which the individual finds difficult to control. In addition, the individual experiences 
physical symptoms, including restlessness or feeling keyed up or on edge; being 
easily fatigued; difficulty concentrating or mind going blank; irritability; muscle 
tension; and sleep disturbance. 
VIII. Substance/medication induced anxiety 
Substance/medication-induced anxiety disorder involves anxiety due to 
substance intoxication or withdrawal or to a medication treatment. In anxiety disorder 
due to another medical condition, anxiety symptoms are the physiological 
consequence of another medical condition. 
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IX. Anxious depression 
 In anxious depression, anxiety, tension or agitation accompanies overt 
depressive affect. Over 60% of anxious patients eventually have symptoms of 
depression. Other patients are chronically depressed with intermittent exacerbations of 
anxiety symptoms. 
X. Obsessive and compulsive disorder 
Patient usually has obsessions and compulsions: 
Obsessions: 
• Recurrent and persistent thoughts, impulses, or images  
• Viewed by patient as intrusive and inappropriate and cause marked anxiety or 
distress.  
• Recognized as a product of his or her own mind. 
Compulsions: 
• Repetitive behaviors or mental acts  
• Performed in response to an obsession, or according to rules that must be applied 
rigidly.  
• Generally not connected in a realistic way with what they are designed to neutralize 
or prevent or are clearly excessive. 
3.1.6 Pathophysiology of anxiety disorder29-34
 
Several preclinical evidence now point to the amygdala as the major mediator 
of stress response, fear and anxiety. The major mediators of anxiety disorder appear to 
be Norepinephrine, Serotonin and GABA. 
 
         GABA is one of the most widely distributed neurotransmitters in the 
mammalian brain, as it is expressed in about 30% of all synapse
. 
GABA is an 
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inhibitory transmitter and therefore reduced the firing rate of excitatory neurons with 
which it is in contact. In various animal models of anxiety, the facilitation of 
GABAergic activity is associated with a reduction in anxiety. 
         Noradrenaline is the neurotransmitter most closely associated with peripheral 
and central stress response. Drugs that stimulate alpha 2 receptors such as clonidine 
diminishes the anxiety state by reducing the release of noradrenaline. Patients with 
panic disorders have increased sensitivity to challenge with isoproterenol because of 
increased peripheral beta receptor sensitivity. 
        Several experimental studies have suggested that a reduction in serotonin in 
the brain results in anxiolysis. Serotonin pathway originating in the dorsal raphe 
nucleus and innervating the amygdala and frontal cortex facilitate avoidance behavior 
in response to distal threat. This pathway involves 5-HT2A/2C and 5-HT3 post synaptic 
receptors and may be relevant to generalized anxiety disorder. A separate pathway 
from the dorsal raphe nucleus and innervating the periventricular and periaqueductal 
grey region inhibit inborn fight or flight reactions in 5HT1A receptors and may be 
relevant to panic attacks. With chronic stress, the serotonin pathway connecting the 
median raphe nucleus to the hippocampus, likely mediated by postsynaptic 5HT1A 
receptor may be relevant to avoiding and numbing found in post traumatic stress 
disorders
. 
Several neuropeptides have been shown to play a role in anxiety but so far 
none has been developed as a drug largely because of their poor pharmacokinetic 
properties and difficulty in penetrating the blood brain barrier. 
        Angiotensin peptides – Angiotensin Converting Enzyme inhibitors like 
captopril, has anxiolytic activity in both experimental and clinical studies. It has 
recently been shown that the angiotensin 1 receptor antagonist, Losartan has 
anxiolytic properties whereas the angiotensin 2 antagonists are inactive. 
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       Cholecystokinin ligands – agonists of the central cholecystokinin receptors 
cause anxiety and precipitate panic attacks in predisposed individuals. Two types of 
Cholecystokinin receptors have been identified, CCK-A and CCK-B, both of which 
occur in mammalian brain. CCK-B agonists initiate anxiety while the antagonists are 
anxiolytic in both experimental and clinical situations. Neurokinin receptor ligands – 
There are two types of Neurokinin receptors in the brain namely NK1 and NK2. NK 2 
agonists have been found to be anxiogenic while the antagonists are anxiolytic at least 
in animal studies. Some NK 1 antagonists have also been shown to be anxiolytic in 
experimental studies. 
        Corticotrophin releasing factor ligands – alpha helical CRF has been shown to 
block the anxiogenic effects of alcohol withdrawal in rats. It is possible that CRF 
interacts with neuropeptide Y receptors; NPY1 receptor agonists to have anticonflict 
effects in animal studies. 
       Adenosine receptor ligands – the adenosine receptor antagonist, caffeine, 
induces anxiety in both animals and humans while agonists have anxiolytic effects. 
         The results of studies investigating neuroactive steroid levels in patients with 
anxiety disorders are conflicting. Brain-derived pregnane steroids can potently and 
specifically enhance GABAA receptor functions. In addition, further studies are 
needed to determine the precise role of neuroactive steroids in the treatment of 
anxiety symptoms; pharmacological agents used to treat the symptoms of anxiety 
disorders often alter brain steroid levels, and understanding the role of these changes 
in steroid levels in the future lead to more specific and effective drug treatments. 
         Several lines of investigators support the involvement of the opioid receptor 
system in the regulation of anxiety. The most compelling evidence for the 
involvement of the delta opioid receptor system in anxiety comes from a study on 
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delta opioid receptor knockout mice. Specifically, delta opioid receptor deficient mice 
exhibit anxiogenic – like phenotype. The modulation of anxiety-like behavior by delta 
opioid receptor agonists may prove to be a useful clinical alternative to treat anxiety 
disorders that are resistant to typical anxiolytics. 
         Bombesin (BB), an amphibian peptide and its mammalian counterparts 
[various forms of neuromedin B (NMB)] and Gastrin Releasing Peptide (GRP), elicit 
their effects through various BB receptor subtypes. Neuromedin B binds 
preferentially to BB 1 subtype and GRP binds to BB2 receptor. BB and NMB 
increased the firing rate of serotonin cells in the dorsal raphe nucleus. Because 
reduced Serotonin release has been linked to reduced anxiety. Antagonists of the 
excitatory actions of BB like peptides on dorsal raphe nucleus serotonin neurons 
might be expected to decrease anxiety. 
3.1.7 Management of Anxiety23, 35, 29
 
Anxiety disorders are the most prevalent of psychiatric disorders, yet less than 
30% of individuals who suffer from anxiety disorders seek treatment. People with 
anxiety disorders can benefit from a variety of treatments and services. Following an 
accurate diagnosis, possible treatments include psychological treatments and 
mediation. 
Psychological treatments 
Psychotherapy is almost always the treatment of choice except in cases where 
anxiety is so severe that immediate relief is necessary to restore functioning and to 
prevent immediate and severe consequences. This includes the following: 
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 Behavioral therapies:  
These focus on using techniques such as guided imagery, relaxation training, 
biofeedback (to control stress and muscle tension); progressive desensitization, 
flooding as means to reduce anxiety responses or eliminate specific phobias. The 
person is gradually exposed to the object or situation that is feared. At first, the 
exposure may be only through pictures or audiotapes. Later, if possible, the person 
actually confronts the feared object or situation. Often the therapist will accompany 
him or her to provide support and guidance. 
 Cognitive-behavioral therapy (CBT):  
In this therapy, people learn to deal with fears by modifying the ways they 
think and behave. A major aim of CBT and behavioral therapy is to reduce anxiety by 
eliminating beliefs or behaviors that help to maintain the anxiety disorder. Research 
has shown that CBT is effective for several anxiety disorders, particularly panic 
disorder and social phobia. It has two components. The cognitive component helps 
people change thinking patterns that keep them from overcoming their fears. The 
behavioral component of CBT seeks to change people's reactions to anxiety-
provoking situations. A key element of this component is exposure, in which people 
confront the things they fear, i.e., CBT addresses underlying ―automatic‖ thoughts 
and feelings that result from fear, as well as specific techniques to reduce or replace 
maladaptive behavior patterns. 
 Psychotherapy:  
Psychotherapy centers on resolution of conflicts and stresses, as well as the 
developmental aspects of anxiety disorders solely through talk therapy. Psychotherapy 
involves talking with a trained mental health professional, such as a psychiatrist, 
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psychologist, social worker, or counselor to learn how to deal with problems like 
anxiety disorders. 
 Psychodynamic therapy:  
This therapy, first suggested by Freud, is based on the premise that primary 
sources of abnormal behavior are unresolved past conflicts and the possibility that 
unacceptable unconscious impulses will enter consciousness. 
 Family therapy and parent training:  
Here the focus is on the family and its dynamics. This is based on the 
assumption that the individuals of a family cannot improve without understanding the 
conflicts that are to be found in the interactions of the family members. Thus, each 
member is expected to contribute. 
Pharmacotherapy
2, 23, 29, 36, 37, 39 
II.ANTIANXIETY DRUG 
1. Benzodiazepines 
 Diazepam 
 Chlordiazepoxide 
 Oxazepam 
 Lorazepam 
 Alprazolam 
2. Azapirones 
 Buspirone 
 Gepirone 
 Ispapirone 
3. β blocker 
 Proponalol 
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4. Sedative antihistaminic 
 Hydroxyzine 
5. Antidepressants 
 Selective serotonin reuptake inhibitor(SSRIS) 
 Tricyclic antidepressants 
 Serotonin and nor adrenaline reuptake inhibitors(SNRIS) 
 Benzodiazepines 
  Chlordiazepoxide and diazepam were introduced around 1960 as antianxiety drugs. 
Some members have a slow and prolonged action; relieve anxiety at low dose 
without producing significant CNS depression. They have a selective taming effect on 
aggressive animals and suppress induced aggression. they also suppress the 
performance impairing effect of punishment. In contrast to barbiturates, they are more 
selective for the limbic system and have proven clinically better in both quality of 
improvement in anxiety and stress related symptoms. 
At anti-anxiety doses, cardiovascular and respiratory depression is minor. 
Benzodiazepines primarily inhibitory GABAergic transmission but other additional 
mechanism of action has been suggested. Higher dose induce sleep and impair 
performance. 
Mechanism of action 
Affect neurons that have receptors for the neurotransmitter GABA  
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               Fig.1. Mechanism of action of benzodiazepines 
Benzodiazepines potentiate GABA→ increase frequency of ch.loride ion channel 
opening→ causes hyper polarization→ raise firing threshold→ and thus inhibits the 
formation of action potential→ inhibitory effects on different sites on brain especially 
motor cortex and limbic system. 
GABA- inhibitory transmitter in brain regions 
 Limbic system(alter mood) 
 RAS (cause drowsiness) 
 Motor cortex(relax muscle) 
Adverse effect 
Side effect occurs in the use to relieve anxiety are 
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 Sedation 
 Psychomotor and cognitive impairment 
 Increased appetite and weight gain 
 Confusional state 
Use: 
1. Anxiety disorders:    
 Short term relief of severe anxiety 
 General anxiety disorder 
 Obsessive compulsive disorder 
 Panic attack with depression Alprazolam (Antidepressant effect)  
2. Sleep disorders (Insomnia). 
  Triazolam, Lorazepam, Flurazepam  
3. Treatment of epilepsy 
 Diazepam – Lorazepam  
4. in anesthesia    
    Preanesthetic medication (diazepam). 
     Induction of anesthesia (Midazolam, IV) 
β adrenergic blocking agent 
No overt central effects are produced by propranolol. However, subtle 
behavioral changes, forgetfulness, increased dreaming and nightmares have been 
reported with long term use of relatively high doses. Proponalol suppresses anxiety in 
short-term stressful situations, but this is due to peripheral rather than a specific 
central action 
                                                                                             Review Of Literature 
 
Institute of Pharmacology, MMC. Page 24 
 
Many symptomps of anxiety (palpitation, rise in BP, shaking, tremor, 
gastrointestinal hurrying, etc.) are due to sympathetic over activity, and these 
symptoms reinforce anxiety. Propanalol and other nonselective β blockers help 
anxious patients troubled by these symptoms, by cutting the vicious cycle and provide 
symptomatic relief. They do not affect the psychological symptoms such as worry, 
tension and fear, but are valuable in acutely stressful situations (examination fear, 
unaccustomed public appearance, etc...). They may be used for performance/ 
situational anxiety or as adjuvant to BZDs .the role of β blockers in anxiety disorders 
is quite limited. 
Hydroxyzine 
        An H1 antihistaminic with sedative, antiemetic, antimuscarinic and 
spasmolytic properties. It is claimed to have selective anxiolytic action, but the 
accompanying sedation is quite marked. Hydroxyzine may be used in reactive anxiety 
or that associated with marked autonomic symptoms. Due to antihistaminic and 
sedative property, it is useful in pruritus and urticaria. 
Antidepressants 
Antidepressants were developed to treat depression but are also effective for 
anxiety disorders. Although these medications begin to alter brain chemistry after the 
very first dose, their full effect requires a series of changes to occur; it is usually about 
4 to 6 weeks before symptoms start to fade. It is important to continue taking these 
medications long enough to let them work 
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Selective Serotonin Reuptake Inhibitors 
The selective serotonin reuptake inhibitors (SSRIs) represent a chemically 
diverse class of agent that have as their primary action the inhibition of the serotonin 
transporter (SERT) 
Fluoxetine was introduced in the US in 1988 and quickly became one of the 
most commonly prescribed medications in medical practice. The development of 
fluoxetine emerged out of the search for chemicals that had high affinity for 
monoamine receptors but lacked the affinity for histamine, acetyl choline, and alpha 
adrenoceptors that is seen with the tricyclic antidepressants. There are currently six 
available SSRIs, and they are the most common antidepressants in clinical use. In 
addition to their use in major depression, SSRIs have indications in GAD, PTSD, 
OCD, panic disorder, PMDD, and bulimia. SSRIs have fewer side effects than older 
antidepressants, but they sometimes produce slight nausea or jitters when people first 
start to take them. Other adverse effect related to the serotonergic effects of SSRIs 
includes an increase in headaches and insomnia or hypersomnia. 
Selective Serotonin–Norepinephrine Reuptake Inhibitors 
The SNRIs include venlafaxine, its metabolite desvenlafaxine, and duloxetine. 
Another SNRI, milnacipran, has been approved for the approved for the treatment of 
fibromyalgia in the USA but has been studied extensively as an antidepressant. In 
addition to their use in major depression, other applications of the SNRIs include the 
treatment of pain disorders including neuropathies and fibromyalgia and in the 
treatment of generalized anxiety, stress urinary incontinence, and vasomotor 
symptoms of menopause. SNRIs are chemically unrelated to each other. 
Venlafaxine’s in vivo effects are similar to those of imipramine but with a more 
favorable adverse effect profile. All SNRIs bind the serotonin (SERT) and 
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norepinephrine (NET) transporters, as do the TCAs. However, unlike the TCAs, the 
SNRIs do not have much affinity for the receptors.  
Tricyclic Antidepressants 
Tricyclics are older than SSRIs and work as well as SSRIs for anxiety 
disorders other than OCD. They are also started at low doses that are gradually 
increased. They sometimes cause dizziness, drowsiness, dry mouth, and weight gain, 
which can usually be corrected by changing the dosage or switching to another 
tricyclic medication. Tricyclics include imipramine which is prescribed for panic 
disorder and GAD, and clomipramine which is the only tricyclic antidepressant useful 
for treating OCD. 
5-HT2 Antagonist  
Two antidepressant are thought to as act primarily as antagonists at the 5-
HT2receptor: Trazodone and Nefazodone. Trazodone’s structure includes a triazolo 
moiety that is thought to impart antidepressant effect. Its primary metabolite, m- 
chlorphenylpiperazine (m-cpp), is a potent 5-HT2 antagonist. Trazodone was among 
the most commonly prescribed antidepressant until it was supplanted by the SSRIs in 
the late 1980s. The most commonly use of   trazodone in current practice is as an 
unlabeled hypnotic, since it is highly sedating and not associated with tolerance or 
dependence. 
Monoamine Oxidase Inhibitors 
Monoamine oxidase inhibitors (MAOIs) were introduced in the 1950s but are 
now rarely used in clinical practice because of toxicity and potentially lethal food and 
drug interactions. Their primary use now is in the treatment of depression 
unresponsive to other antidepressants. However, MAOIs have also been used 
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historically to treat anxiety states, including social anxiety and panic disorder. In 
addition, selegiline is used for the treatment of Parkinson’s disease. 
Current MAOIs include the hydrazine derivatives phenelzine and 
isocarboxazid and the non-hydrazines tranylcypromine, selegiline, and moclobemide. 
The hydrazines and tranylcypromine bind irreversibly and nonselectively with MAO-
A and –B, whereas other MAOIs may have more selective or reversible properties. 
Some of the MAOIs such as tranylcypromine resemble amphetamine in chemical 
structure, whereas other MAOIs such as selegiline have amphetamine- like 
metabolites. As a result, these MAOIs tend to have substantial CNS- stimulating 
effects. 
Azapirone  
Buspirone is the first azapirone, a new class of antianxiety drugs. Buspirone 
mimics the antianxiety properties of benzodiazepines but does not interact with 
GABAA receptor. Buspirone relieves anxiety without causing marked sedative, 
hypnotic, or euphoric effects. Unlike benzodiazepines, the drug has no anticonvulsant 
or muscle relaxant properties. The mechanism of anxiolytic action is not clearly. It 
may exert its anxiolytic effects by acting as a partial agonist at brain 5-HT1Areceptors, 
but it also has affinity for brain dopamine D2 receptors. Buspirone treated patient’s 
show no rebound anxiety or withdrawal signs on abrupt discontinuance. The drug is 
not effective in blocking the acute withdrawal syndrome resulting from abrupt 
cessation of use of benzodiazepines or other selective-hypnotics. Buspirone has 
minimal abuse liability. In marked contrast to the benzodiazepines, the anxiolytic 
effect of buspirone may take more than a week to become established, marking the 
drug unsuitable for management of acute anxiety states. The drug is used in 
generalized anxiety states but is less effective in panic disorders. 
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3.2 SLEEP DISORDERS26, 39
 
International Classification of Diseases (ICD-9-CM) classifications for sleep disorders  
      The ICSD consists of four categories. The first category comprises the 
dyssomnias (i.e., the disorders of initiating and maintaining sleep and the disorders of 
excessive sleepiness). The second category, the parasomnias, comprises the disorders 
of arousal, partial arousal, or sleep stage transition, which do not cause a primary 
complaint of insomnia or excessive sleepiness. The third category, sleep disorders 
associated with mental, neurologic, or other medical disorders, comprises disorders 
with a prominent sleep complaint that is felt to be secondary to another condition. The 
fourth category, proposed sleep disorders, includes those disorders for which there is 
insufficient information available to confirm their acceptance as definitive sleep 
disorders. 
1. Dyssomnias 
A. Intrinsic Sleep Disorders 
B. Extrinsic Sleep Disorders 
C. Circadian Rhythm Sleep Disorders 
2. Parasomnias 
A. Arousal Disorders 
B. Sleep-Wake Transition Disorders 
C. Parasomnias Usually Associated with REM sleep 
D. Other Parasomnias 
3. Sleep Disorders Associated with Mental, Neurologic, or Other Medical 
Disorders 
A. Associated with Mental Disorders 
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B. Associated with Neurologic Disorders 
C. Associated with Other Medical Disorders 
4. Proposed Sleep Disorders 
1. Dyssomnias 
The dyssomnias are the disorders that produce either difficulty initiating or 
maintaining sleep or excessive sleepiness. This section is divided into three groups of 
disorders: intrinsic sleep disorders, extrinsic sleep disorders, and circadian rhythm 
sleep disorders. 
1. A. Intrinsic Sleep Disorders 
I. Narcolepsy 
Narcolepsy is a disorder of unknown etiology that is characterized by 
excessive sleepiness that typically is associated with cataplexy and other REM sleep 
phenomena, such as sleep paralysis and hypnagogic hallucinations. 
II. Psychophysiologic insomnia 
Psychophysiologic insomnia is a disorder of somatized tension and learned 
sleep-preventing associations that results in a complaint of insomnia and associated 
decreased functioning during wakefulness 
III. Restless legs syndrome: 
         Restless legs syndrome is characterized by ascending abnormal sensations in 
the legs when they are at rest (e.g. when the patient watches television, or before 
falling asleep) accompanied by a urge to move the legs. It is sometimes present as a 
genetic disorder with autosomal dominant inheritance. Periodic leg movements during 
sleep are repeated, abrupt twitching movements of the legs that may persist for 
minutes to hours. 
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IV. Obstructive sleep apnea: 
        Obstructive sleep apnea is characterized by daytime somnolence with frequent 
nocturnal respiratory pauses and loud snoring. Impaired concentration, decreased 
performance and headaches are also common. 
V. periodic limb movement disorder 
Periodic limb movement disorder is characterized by periodic episodes of 
repetitive and highly stereotyped limb movements that occur during sleep 
1. B. Extrinsic sleeps disorder 
Extrinsic sleep disorders either originate or develop from causes outside of the 
body. External factors are integral in producing these disorders. Removal of the 
external factor usually is associated with resolution of the sleep disturbance unless 
another sleep disorder develops during the course of the sleep disturbance (e.g., 
psychophysiologic insomnia may follow removal of an external factor responsible for 
the development of an adjustment sleep disorder) 
I. Environmental sleep disorder is a sleep disturbance due to a disturbing 
environmental factor that causes a complaint of either insomnia or excessive 
sleepiness 
II. Altitude insomnia is an acute insomnia, usually accompanied by headaches, loss 
of appetite, and fatigue, which occurs following ascent to high altitudes. 
This is a common complaint of mountain climbers or other individuals who sleep in 
high-altitude environments. Symptoms typically occur within 72 hours of exposure. A 
disturbance of respiration that appears to be directly related to lack of inspired oxygen 
is associated with the difficulty in initiating and maintaining sleep 
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III. Insufficient sleep syndrome is a disorder that occurs in an individual who 
persistently fails to obtain sufficient nocturnal sleep required to support normally alert 
wakefulness 
Complications: Chronic mood disturbance, documented work-performance deficits, 
disruption of social functioning, and marital discord may be due to this disorder. 
Traffic accidents or injury at work may result from loss of normal vigilance 
IV. Inadequate sleep hygiene is a sleep disorder due to the performance of daily 
living activities that are inconsistent with the maintenance of good quality sleep and 
full daytime alertness. 
1. C. Circadian Rhythm Sleep Disorders 
Circadian rhythm sleep disorders are disorders that are related to the timing of 
sleep within the 24-hour day. Some of these disorders are influenced by the timing of 
the sleep period that is under the individual’s control (e.g., shift work or time-zone 
change), whereas others are disorders of neurologic mechanisms (e.g., irregular sleep-
wake pattern and advanced sleep-phase syndrome). Some of these disorders can be 
present in both an intrinsic and extrinsic form; however, their common linkage 
through chronobiologic, pathophysiologic mechanisms dictates their recognition as a 
homogeneous group of disorders 
I. Time zone change (jet lag) syndrome consists of varying degrees of difficulties in 
initiating or maintaining sleep, excessive sleepiness, decrements in subjective daytime 
alertness and performance, and somatic symptoms (largely related to gastrointestinal 
function) following rapid travel across multiple time zones. 
Complications: Subjective distress about not sleeping well and social embarrassment 
because of falling asleep at inappropriate times may occur. Self-treatment, especially 
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involving the use of large amounts of alcohol, may complicate the clinical picture. 
Menstrual irregularities in female air crew have been attributed to repeated jet lag 
II Delayed sleep-phase syndrome is a disorder in which the major sleep episode is 
delayed in relation to the desired clock time, resulting in symptoms of sleep-onset 
insomnia or difficulty in awakening at the desired time. 
Complications: Occupational, school, and social dysfunctions of varying degrees are 
a typical accompaniment of DSPS and are often the major complaint that brings the 
patient to clinical attention. Absenteeism and chronic tardiness are poorly tolerated in 
the school and day-shift work settings, and many patients with DSPS come to be 
regarded as lazy, unmotivated, or mentally ill by their families, peers, and superiors in 
the business or school environment, even in the context of otherwise good social and 
mental functioning 
2. parasomnia 
The parasomnias (i.e., the disorders of arousal, partial arousal, and sleep-stage 
transition) are disorders that intrude into the sleep process and are not primarily 
disorders of sleep and wake states per se. These disorders are manifestations of central 
nervous system activation, usually transmitted through skeletal muscle or autonomic 
nervous system channels. They are divided into four groups: arousal disorders, sleep-
wake transition disorders, parasomnias usually associated with rapid eye movement 
(REM) sleep, and other parasomnias. 
2. A. Arousal Disorders 
Arousal disorders are manifestations of partial arousal that occur during sleep. 
These disorders are the ―classic‖ arousal disorders that appear to be primarily 
disorders of normal arousal mechanisms. 
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I. Sleep walking consists of a series of complex behaviors that are initiated during 
slow-wave sleep and result in walking during sleep. 
II. Sleep terrors are characterized by a sudden arousal from slow-wave sleep with a 
piercing scream or cry, accompanied by autonomic and behavioral manifestations of 
intense fear 
2. B. Sleep-Wake Transition Disorders 
Sleep-wake transition disorders are those that occur mainly during the 
transition from wakefulness to sleep or from one sleep stage to another. Although 
under some circumstances these disorders can occur within specific sleep stages, this 
is usually the exception rather than the rule. 
I. Sleep starts are sudden, brief contractions of the legs, sometimes also involving the 
arms and head, which occur at sleep onset 
II. Sleep talking is the utterance of speech or sounds during sleep without 
simultaneous subjective detailed awareness of the event. 
2. C. Parasomnias Usually Associated with REM sleep 
The parasomnias usually associated with REM sleep have their onset during 
the REM sleep stage; some of these REM sleep parasomnias do occur during other 
sleep stages, but this occurrence is rare. 
I. Nightmares are frightening dreams that usually awaken the sleeper from REM 
sleep. 
II. Sleep paralysis consists of a period of inability to perform voluntary movements 
at sleep onset (hypnagogic or predormital form) or upon awakening, either during the 
night or in the morning (hypnopompic or postdormital form) 
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3. Sleep Disorders Associated with Mental, Neurologic, or Other Medical 
Disorders  
This section lists those disorders that are not primarily sleep disorders but are 
mental, neurologic, or other medical disorders that have either sleep disturbance or 
excessive sleepiness as a major feature of the disorder. This listing of mental, 
neurologic, or other medical disorders is not intended to include all mental and 
medical disorders that affect sleep or wakefulness. It does include, however, those 
disorders most commonly associated with sleep symptoms. 
3. A. Sleep Disorders Associated with Mental Disorders 
Although most mental disorders can have an associated sleep disturbance, the 
psychoses, mood disorders, anxiety disorders, panic disorder, and alcoholism are 
presented here because they are commonly seen in patients presenting with sleep 
complaints and need to be considered in differential diagnoses. Panic disorder, one of 
the anxiety disorders, has a separate text because this disorder can produce only a 
sleep complaint.  
I. The anxiety disorders are mental disorders that are characterized by symptoms of 
anxiety and avoidance behavior. The sleep disturbance associated with anxiety 
disorders is characterized by sleep-onset or maintenance insomnia due to excessive 
anxiety and apprehensive expectation about one or more life circumstances  
II. Panic disorder is a mental disorder that is characterized by discrete periods of 
intense fear or discomfort with several somatic symptoms that occur unexpectedly 
and without organic precipitation. Panic episodes can be associated with sudden 
awakenings from sleep.  
 
 
                                                                                             Review Of Literature 
 
Institute of Pharmacology, MMC. Page 35 
 
3. B. Sleep Disorders Associated with Neurologic Disorders 
Neurologic disorders that are commonly associated with sleep disturbance are 
listed and described here. Cerebral degenerative disorders, dementia, and 
Parkinsonism are commonly recognized neurologic disorders that are associated with 
sleep disturbance. Epilepsy may be exacerbated by sleep disturbance; epileptic 
phenomena may occur predominantly during sleep.  
I. Dementia refers to a loss of memory and other intellectual functions due to a 
chronic, progressive degenerative disease of the brain. Sleep disturbance in demented 
patients is characterized by delirium, agitation, combativeness, wandering, and 
vocalization without ostensible purpose and occurring during early evening or 
nighttime hours.  
II. Parkinsonism refers to a group of neurologic disorders characterized by 
hypokinesia, tremor, and muscular rigidity. Insomnia is the most common sleep-
related symptom in patients with Parkinsonism.  
4. Proposed Sleep Disorders 
This section lists those disorders for which there is insufficient information 
available to confirm the unequivocal existence of the disorder (e.g., sub wakefulness 
syndrome). Most newly described sleep disorders fall under this category until 
replicated data are available in the literature (e.g., sleep choking syndrome). Some 
sleep disorders that are controversial as to whether they are the extremes of the 
normal range or represent a definitive disorder of sleep also are included here (e.g., 
short and long sleepers).   
I.  A short sleeper is an individual who habitually sleeps substantially less during a 
24-hour period than is expected for a person in his or her age group. 
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II. Terrifying hypnagogic hallucinations are terrifying dream experiences that occur 
at sleep onset and are similar to, or at times indistinguishable from, those dreams that 
take place within sleep.  
III. Pregnancy-associated sleep disorder is characterized by the occurrence of either 
insomnia or excessive sleepiness that develops in the course of pregnancy the sleep 
disorder associated with pregnancy usually is biphasic. It typically begins with 
excessive sleepiness and can progress to severe insomnia. In rare instances, 
nightmares sleep terrors, and postpartum psychosis may occur. 
3.2.1 Pathophysiology of sleep disorders: 40 
           The physiological mechanisms regulating the sleep-wake rhythm are not 
completely known. There is evidence that histaminergic, cholinergic, glutamatergic, 
and adrenergic neurons are more active during waking than during the NREM sleep 
stage. Via their ascending thalamopetal projections, these neurons excite 
thalamocortical pathways and inhibit GABA-ergic neurons. During sleep, input from 
the brainstem decreases, giving rise to diminished thalamocortical activity and 
disinhibition of the GABA neurons. The shift in balance between excitatory and 
inhibitory neuron groups underlies a circadian change in sleep propensity, causing it 
to remain low in the morning, to increase towards early afternoon (middle siesta), 
then to decline again, and finally to reach its peak before midnight. As the margin 
between excitatory and inhibitory activity decreases with age, there is an increasing 
tendency towards shortened daytime sleep periods and more frequent interruption of 
nocturnal sleep. Imbalance between the excitatory and inhibitory neurotransmission 
with more shift toward excitatory system underlies many of the sleeping disorders. 
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3.2.2 Sedative-Hypnotic Drugs2
 
A  Sedative is a drug that produces a relaxing, calming effect. 
1. Barbiturates 
     Long acting       Short acting Ultra-short acting 
Phenobarbitone      1.   Butobarbitone 
     2.  Pentobarbitone 
      1.  Thipentone 
      2. Methohexitone 
 
2. Benzodiazepines 
 Diazepam 
 Flurazepam 
 Nitrazepam 
 Alprazolam 
 Temazepam 
3. Newer nonbenzodiazipine  
 Zopiclone 
 Zolpidem 
 Zaleplon 
Treatment of insomnia: 41 
     Management of insomnia is initially based on whether the individual has 
experienced a short-term, transient, or chronic sleep disturbance. Transient insomnia 
resolves quickly and should be treated with good sleep hygiene and careful use of 
sedative hypnotics. For treating short term insomnia that is lasting up to 3 weeks, non 
pharmacologic treatment is important and if sedative hypnotics are used, care must be 
taken to prevent the development of tolerance or dependence. Chronic insomnia 
requires careful assessment for the medical reason for the insomnia, as well as 
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nonpharmacologic techniques and careful and less frequent use of sedative-hypnotics 
to prevent tolerance and dependence. 
Non pharmacologic therapy: 
   • Stimulus control therapy 
   • Sleep restriction 
   • Relaxation therapy 
  • Cognitive therapy 
  • Paradoxical intention 
   • Sleep hygiene 
Pharmacologic therapy: 2, 42 
Benzodiazepines: 
      The most commonly used treatment for insomnia has been the 
benzodiazepines. Benzodiazepines reduce sleep latency and increase total sleep time. 
Benzodiazepines increase stage 2 sleep while decrease REM, stage 3, stage 4 sleep. 
As REM sleep is interfered with, increased incidence of rebound insomnia and night 
mares occurs. Prolonged sedation and cognitive and psychomotor impairment are 
concerns in the elderly. There is an association between falls and hip fractures and use 
of benzodiazepines with long elimination half-lives. Drug dependency and abuse may 
pose a problem if used for a longer period. Commonly used benzodiazepines as 
hypnotic agents include Estazolam, Flurazepam Quazepam, Temazepam, Triazolam, 
Nitrazepam, Alprazolam. 
Zolpidem: 
       Zolpidem is a selective GABA Benzodiazepines – 1 receptor agonist. It 
reduces sleep latency, nocturnal awakenings increases total sleep time and does not 
appear to have significant effects on next-day psychomotor performance. Treatment is 
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initiated with 5 mg and can be increased to 10 mg as a daily dose and optimally 
should not exceed 4 weeks to minimize tolerance and dependence. 
Zaleplon:
 
       Zaleplon has rapid onset of action, short half-life of 1 hour. Effective in 
decreasing time of onset to sleep onset but not for reducing nighttime awakening or 
for increasing the total sleep time. It does not interfere with stages of sleep and so 
rebound insomnia and nightmares are in fewer incidences when compared to 
Benzodiazepines.
42 
Antihistamines: 
        Antihistamines are effective in the treatment of mild insomnia and are 
generally safe. diphenhydramine and doxylamine are preferred agents. 
Amino acid L-Tryptophan: 
      Tryptophan is a precursor of serotonin and was once a popular natural 
sedative. Cases of Eosinophilia-myalgia syndrome removed this product from the 
market. 
Antidepressants:
 
      Antidepressants are alternatives for patient with non restorative sleep who 
should not receive benzodiazepines, especially those who have depression, pain or a 
risk of substance abuse. Sedative antidepressants such as amitriptyline, doxepin and 
nortriptyline are effective for inducing sleep continuity. Trazodone is used for 
insomnia patients who are prone to substance abuse. It is frequently used in patients 
with SSRIs and bupropion-induced insomnia in doses of 25 to 75 mg.
42 
Melatonin: 
    Melatonin is a hormone released by the pineal gland during the night. It is 
promoted as a sleep aid. Most studies with melatonin are in children with neurological 
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impairment and in individuals with jet lag. Ramelteon was designed to be a chemical 
mimic of the endogenous hormone melatonin and is more potent than melatonin and 
was recently approved for treatment of insomnia characterized by difficulty with sleep 
onset. It has the distinction of being the only hypnotic prescription that is not a 
controlled substance. 
Valerian: 
    Valerian is an herbal sleep remedy. Its mechanism may involve inhibition of 
an enzyme that breaks down GABA. 
3.3 Role of Natural herbal treatment in anxiety & sleep disorders:
 
      Plants have played a significant role in maintaining human health and 
improving the quality of human life for thousands of years and have served humans 
well as valuable components of medicines, seasonings, beverages, cosmetics and 
dyes. Herbal medicine is based on the premise that plants contain natural substances 
that can promote health and alleviate illness. Herbal drugs or medicinal plants, their 
extracts and their isolated compounds have demonstrated spectrum of biological 
activities. Such have been used and continued to be used as medicine in folklore or 
food supplement for various disorders. Ethno pharmacological studies on such herbs 
or medicinally important plants continue to interest investigators throughout the 
world.
43 
Among the herbal remedies for anxiety& sleep disorders, notable are 
Valeriana wallichii, Nardostachys jatamansi, Geodorum densiflorum, Lippia 
nodiflora, Baccharis uncinella, Thuja occidentalis, Casimiroa pringlei, Nerium 
oleander 
  There are many plants which have not been subjected to a through scientific 
evaluation. One such plant is Amomum subulatum belongs to the family of 
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zingiberaceae. The seed of the plant not been so far subjected to sedative and 
antianxiety activity screening. Hence the present study was carried out to explore the 
sedative and antianxiety activity of various extract of Amomum subulatum seeds. 
 
3.4 PHAMACOLOGICAL INVESTIGATION OF Amomum 
subulatum PLANT EXTRACTS 
       Jafri MA et al., (2001) evaluated the gastric antiulcerogenic effect of large 
cardamom. A crude methanolic extract and its different fractions, viz. essential oil, 
petroleum ether (60–80°), ethyl acetate and methanolic fractions, were studied in rats 
for their ability to inhibit the gastric lesions induced by aspirin, ethanol and pylorus 
ligature. In addition their effects on wall mucus, output of gastric acid and pepsin 
concentration were recorded. The crude methanolic extract of A. subulatum and its 
fractions, viz. essential oil, petroleum ether and ethyl acetate, inhibited gastric lesions 
induced by ethanol significantly, but not those which were induced by pylorus 
ligation and aspirin. However, ethyl acetate fraction increased the wall mucus in 
pylorus ligated rats. The results suggest a direct protective effect of ethyl acetate 
fraction on gastric mucosal barrier. The observation of decrease in gastric motility by 
essential oil and petroleum ether fractions suggest the gastro protective action of the 
test drug.
44 
         Hiroe Kikuzaki et al., (2001) evaluated the ethyl acetate-soluble fraction of the 
fruits of Amomum subulatum showed a high free radical-scavenging activity using 1, 
1-diphenyl-2-picrylhydrazyl (DPPH) method. Four compounds were isolated from the 
ethyl acetate-soluble fraction, and their structures were ascribed to 
protocatechualdehyde (1), protocatechuic acid (2), 1,7 bis(3,4- 
dihydroxyphenyl)hepta-4E,6E-dien-3-one (3) and 2,3,7-trihydroxy-5-(3,4-dihydroxy-
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E - styryl)-6,7,8,9-tetrahydro-5H-benzocycloheptene (4) on the basis of spectroscopic 
evidence. DPPH radical-scavenging activity of these compounds was measured by 
colorimetric analysis. Compounds 1 and 3 showed stronger activity than natural 
antioxidants such as α-tocopherol and L-ascorbic acid. Compounds 2 and 4 were 
comparable to α-tocopherol and L-ascorbic acid.45 
         Anwar Jamal et al., (2005) evaluated the antiulcerogenic activity of seed of 
Eletarria cardamom and Amomum subulatum Roxb.  Their essential oils and 
petroleum ether soluble fractions were studied in rats for their ability to inhibit gastric 
lesions induced by aspirin and ethanol. Both the fractions of drugs inhibited formation 
of gastric lesions significantly. Fractions of small cardamom were found to be better 
than large cardamom.
46 
       The Modulatory effect of spice extracts on iron-induced lipid peroxidation in 
rat liver by Yadav AS, Bhatnagar D., (2007)   reported the inhibition of lipid 
peroxidation in rat liver homogenate. The activity can be attributed to their 
polyphenol content, strong reducing power and superoxide radical scavenging 
activity.
47 
      Kapoor IPS et al., (2008) evaluated the antioxidant activity of the essential oil 
and oleoresins against mustard oil by peroxide, p-anisidine, thiobarbituric acid, total 
carbonyl, ferric thiocyanate and the 2, 2’-diphenyl-1-picrylhydrazyl (DPPH) radical 
scavenging methods. The essential oil showed signifcant activities in all antioxidant 
assays and contained a high level of total phenolic content; however, oleoresins have 
been observed as better antioxidants than butylated hydroxytoluene. Further, the 
essential oil showed 100% inhibition against Aspergillus ﬂavus at a 6 µl dose. For 
other tested fungi, the essential oil and all oleoresins showed good to moderate 
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inhibitory effects. Hence, these could be used as natural food preservatives, though 
the essential oil is more active than the oleoresins.
48 
       Mihir Y Parmar et al., (2009) evaluated the hepatoprotective activity of 
methanolic extract of Amomum subulatum Roxb (Zingiberaceae) seeds was studied 
against 20 % ethanol (3.76 g/kg/days, p.o for 18 days) induced liver damage in rats. 
Ethanol produced significant changes in various liver parameters such as functional 
(thiopentone-induced sleeping time) and physical (increased liver weight and 
volume). It also increased the biochemical parameters such as serum glutamate 
oxaloacetic transaminase and glutamate pyruvic transaminase, alkaline phosphatase, 
total and direct bilirubin, total cholesterol, and triglyceride and decreased total protein 
along with changes in histological parameters (damage to hepatocytes). Treatment 
with methanolic extract of A. subulatum (100 and 300 mg/kg/day, p.o. for 18 days) 
and silymarin significantly prevented the functional, physical, biochemical and 
histological changes induced by ethanol, indicating the recovery of hepatic cells. 
These results demonstrate that methanolic extract of A. subulatum seeds possessed the 
hepatoprotective activity.
49 
       Aneja KR, Radhika Joshi., (2009) evaluated the in vitro antimicrobial activity 
of Amomum subulatum and Elettaria cardamomum extracts (acetone, ethanol and 
methanol) of fruit against Streptococcus mutans, Staphylococcus aureus, 
Lactobacillus acidophilus, Candida albicans and Saccharomyces cerevisiae. 
Minimum inhibitory concentrations (MIC) of the extracts were determined against the 
four selected microorganisms showing zones of inhibition ≥10mm. This study depicts 
that ethanol and acetone extracts of fruits of Amomum subulatum and Elettaria 
cardamomum can be used as a potential source of novel antimicrobial agents used to 
cure dental caries.
50 
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       Shukla SH et al., (2010) describe analgesic activity of Amomum subulatum 
Roxb. The methanolic extract at dose 100 mg/kg and 300 mg/kg and ethyl acetate 
extract at dose 200 mg/kg and 400 mg/kg of seeds of plant were investigated for the 
analgesic activity using hot plate method and writhing method. The analgesic action 
of both the extracts can be attributed to the blockage of release of endogenous 
mediators of pain i.e. prostaglandins. It suggests that the plant has some inhibitory 
action on cyclooxygenase pathway which is involved in synthesis of prostaglandins 
biosynthesis. Both methanolic and ethyl acetate extract of seeds of Amomum 
subulatum possessed significant (p<0.001) analgesic activity.
51 
      Alam K et al., (2011) explored the anti-inflammatory activity of ethanolic and 
aqueous extract of fruit of Amomum subulatum. Dose of 100 mg/ml and 200 mg/ml of 
ethanolic and aqueous extract were evaluated for their anti-inflammatory activity 
against carrageenan induced paw edema in rats. Both the extracts showed anti-
inflammatory activity in dose dependant manner as compared with standard drug 
Diclofenac sodium 100 mg/ml. The data were found statistically significant by using 
one way ANOVA (P< 0.001).
52 
       Khare Divya Prakash et al.,(2012) from this study the ethanolic and aqueous 
extracts of leaves of Amomum subulatum is evaluated for antioxidant activity by the 
1,1Diphenyl -2 picrylhydrazyle (DPPH) free radical scavenging activity, β-carotene 
bleaching assay and total phenolic contents methods. The ethanolic extract showed 
significant antioxidant activity. The IC50 of ethanolic extract, total phenolic content, 
and mean antioxidant activity are 8.25±2.0, 11.04±0.2 and 41.2±1.5 µg/ml 
respectively and that of ascorbic acid was 2.0±0.14 µg/ml whereas BHA was found to 
be 50.3±0.6 µg/ml. The study showed that the ethanolic extract consumption could 
exert beneficial effects due to its antioxidant activity.
53 
                                                                                             Review Of Literature 
 
Institute of Pharmacology, MMC. Page 45 
 
      Vavaiya RB et al., (2012) evaluated Antidiabetic activity of Amomum 
subulatum Roxb. Seed in fructose fed metabolic syndrome in rat. Acetone and 
methanol extracts were assayed for total phenolic contents by UV method. Presence 
of protocatechuic acid was estimated by HPTLC method. Oral administration of both 
A. subulatum extracts revealed a significant (P<0.001) increment of serum insulin 
levels, higher reduction in hyperglycemia when compared to the diabetic control rats 
(P<0.001). The histological studies of the endocrine region of pancreas of diabetic 
animals revealed that shrinkage of β cells of islets of langerhans. Animals treated with 
both extracts of Amomum subulatum, revealed restoration of β-cells. This activity of 
acetone and methanolic extract might be due to presence of phenolics like 
protocatechuic acid.
54 
       Bharat Sharma, Neeru Vasudeva., (2016) studied the in vitro antimicrobial 
activities of leaf extracts in different solvents viz., aqueous, methanol, petroleum 
ether, ethyl acetate of selected plant Amomum subulatum were accessed by agar well 
diffusion method against various bacterial and fungal strains. The result revealed that 
methanolic extract has significant potential to inhibit the growth of pathogenic 
bacterial and fungal strains. Other extracts of leaves were also found to be effective 
against microbial strains. On the basis of present finding, they concluded that 
Amomum subulatum leaf extracts might be a good candidate in the search for a natural 
antimicrobial agent.
 55 
         Gaurav Garg et al., (2016) studied the antibacterial potential of cardamom 
(Amomum subulatum) against the enteropathogenic and food-spoiler bacterial strains 
Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus 
pumilus. Bacterial cell membrane integrity was damaged and an increase in the 
absorbance at 260nm and 280nm was observed after incubation with cardamom 
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extract. Cardamom extract inhibited the growth of all the bacterial strains tested with 
MIC of 6.24mg/ml for E.coli and 4.16mg/ml for other bacteria. The zone of inhibition 
observed by well diffusion method in presence of extract equivalent to 33.3mg/ml 
cardamom was 15-20mm. Cardamom extract had 10.75mg polyphenol/g dry weight. 
The results indicate good antibacterial activity was found in polyphenol rich 
cardamom methanol extract.
56 
 ANTIANXIETY AND SEDATIVE EFFECT OF OTHER PLANTS 
EXTRACTS 
      The research work deals with the screening of ethanol and chloroform extracts 
of Pachyrrhizus erosus seeds for central nervous system (CNS) depressant activity by 
Mohd Abid et al.,(2006) . The different activities studied were potentiation of 
pentobarbitone-induced sleep, test for locomotor activity, and effect on muscle co-
ordination, antiaggressive and antianxiety activities. The result of the study reflected 
that ethanol extract of the seeds (150 mg/kg, p.o) decreased locomotor activity, 
produced muscle relaxation and showed antianxiety and antiaggressive activity.
57 
      The petroleum ether , chloroform , ethanol and water extracts of  Equisetum 
arvense stems were evaluated for anti-anxiety activity in mice using elevated plus 
maze model, Ketamine induced hypnosis and actophotometer was used to evaluate 
sedative effect with various extracts in mice by Navdeep Singh et al., (2011) the 
results were compared with standard drug diazepam. The ethanolic extract of E. 
arvense (50 and 100 mg/kg) significantly increased the time-spent and the percentage 
of the open arm entries in the elevated plus-maze model which was comparable to 
diazepam. Ethanolic extract (100 mg/kg) prolonged the ketamine-induced total 
sleeping time and decreased the locomotor activity in mice. The results suggest that 
the ethanolic extract of E. arvense seems to possess anxiolytic effect with lower 
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sedative activity than that of diazepam. The results could be attributed to the 
flavonoid content of the ethanolic extract.
58    
     Monalisa Jena, Swati Mishra., (2013) evaluated the  anti anxiety & sedative 
effects of Ethanolic extract of leaves of  Eclipta alba(EEEA) in albino rats using 
thiopental sodium induced sleeping time (TIS), locomotor activity by actophotometer, 
elevated plus maze test. EEEA was administered in 50,100,200&400mg/kg doses PO. 
In the TIS time, the extract in a dose of 200 & 400 mg/kg induced the sleep at an 
earlier stage & prolonged the duration of sleep. The extract at the dose of 400mg 
increased % of entries & time spent in the open arms significantly. The EEEA also 
decreased the locomotor activity in the same dose. The EEEA was found to possess 
both sedative & anxiolytic activity.
59
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 3.5 PLANT PROFILE 
     Amomum subulatum seeds belong to the family of zingiberaceae. 
SYNONYM 
    Cardamom subulatum (Roxb) kuntze. 
BOTANICAL CLASSIFICATION
 60 
Kingdom: Plantae 
Subkingdom: Tracheobionta 
Super division: Spermatophyte 
Class: Liliopsida 
Subclass: Zinziberidae 
Division: Mangnoliophyta 
Order: Zingiberals 
Family: Zingiberaceae 
Genus: Amomum 
Species: amomum subulatum or amomum costatum 
BOTANICAL NAME
 60 
   Amomum subulatum Roxb. 
CLASSICAL& COMMON NAMES
 61 
 Ayurvedic: Prithvikaa, Triputta, Bhadrailaa, Sthula, Elaamahati, Brihad-
Elaa, Nishkuti. 
 Unani: Heel Kalan(Persian); Heel Zakar(Arabic) 
VERNACULAR NAME
 60 
 Tamil- kattu yelam 
 English-large cardamom or greater cardamom 
 Hindi-badi elaichi 
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 Telugu-peddayelaki 
 Malayalam-perelam 
PLANT PICTURE 
  
Fig.2. Fruit and seeds of A. subulatum            Fig.3. Whole plant of A. subulatum                                                                           
 
HABITAT:
 
       Amomum subulatum is native to the Eastern Himalayas; the main production 
regions are Eastern Nepal, India (mostly in the tiny union state Sikkim) and Bhutan. 
More than 50% of the world’s harvests are produced in India.61 
DESCRIPTION:
 
     Amomum subulatumis a tall perennial herb reaching upto 2.5 m in height with 
creeping rhizomes, several erect leafy shoots bearing oblong-lanceolate large leaves 
and short penduncled glabrous spikes. The capsules are upto 2.5 cm long, obcordate, 
brownish, containing many flattened seeds. A native of Himalayas, this plant is now 
cultivated widely in northeast India.
62 
PHYTOCHEMISTRY:
 49, 51 
       From the genus Amomum, a number of derivatives and inaccessible 
metabolites have been reported. By using standard procedures the presence of various 
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chemical constituents on the plant extracts, were screened. Various metabolites have 
been reported such as alkaloids, tannins, terpenoids, flavonoids, saponins, steroid and 
volatile oil (chiefly composed of 1, 8 cineole). 
CHEMICAL CONSTITUENTS:
 60, 63 
       The plant part of Amomum subulatum mainly contains the petunidin, 
glycosides, chalcone, alpinetin, 3, 5-diglucoside, flavonone, subulin, deucocyanidin-
3-0-β-D-glucopyranoside and cardamonin. Acid hydrolysis of subulin yield aglycone, 
subulaurone. Steam distillation of the plant seed yield upto 3% of volatile oil consist 
of (in%) 1,8 cineole(74.0), limonene(10.0), α-terpineol(2.0), terpin-4-d(2.0), α-
pinene(2.0), β-pinene, nerolidol(1.0), myrcene(3.0), sabinene(0.2), γ-lymene(0.2), γ-
terpinene(0.2). 
TRADITIONAL USE: 
60, 61, 64 
 The plant is used in Ayurveda, Unani and Siddha. Seeds are astringent, 
aromatic, hypnotic, cardio tonic, blood purifier, carminative, diuretic, stimulant, 
stomachi, and are also  used in the treatment of neuralgia, gonorrhea, anorexia, eye 
inflammation,fever,cold,chill,malaria,diarrhea,headache,impotence,dyspepsia and 
vomiting. It is also serves as antidote to scorpion sting and snakebite. As a gargle used 
to treat in infection of the teeth and gums; dried powdered seeds given in abdominal 
pain and in heart and liver disorders; powdered seeds are used in cough, vomiting and 
rectum diseases. Crushed fruit applied over the area affected by scorpion bite, also 
given orally. 
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                           5. MATERIALS AND METHODS 
STUDY CENTRE: 
 The study was carried out in the Institute of Pharmacology and animal house, 
Madras Medical College, Chennai-03. 
ANIMALS: 
The present study was conducted after obtained approval from the Institutional 
Animal Ethics Committee, Madras Medical College, Chennai-03. The protocol met 
the requirements of national guidelines of CPCSEA (PROPOSAL NO:  
IAEC/MMC/13/2016) twenty four Swiss albino mice of either sex weight between 
20-30g were procured from the animal house of Madras Medical College, Chennai 03. 
        The animals were maintained under standard laboratory conditions, 
[temperature (25±1) ºc, relative humidity 55%-65% and normal day/dark circle period 
[12hr dark/12 hr light] 
        All the animals included in the study were given standard laboratory feed and 
water ad libitum. The animals were allowed to acclimatize in the laboratory for one 
week.    
DRUGS AND CHEMICALS  
 Diazepam (5mg/kg tablet) 
 Methanol and pet. Ether extracts of Amomum subulatum seeds. 
EQUIPMENTS: 
 Actophotometer    
 Open field apparatus 
 Elevated plus maze 
 Mortar and pestle 
 Stopwatch 
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 Orogastric tube and syringe(1 ml) 
DIAZEPAM: 
    3mg/kg body weight for mice was used as standard sedative and antianxiety 
agents. 
5.1 PLANT MATERIALS AND EXTRACTION PROCEDURE: 
       Seeds of Amomum subulatum Roxb. Were collected from local market in 
Parrys (chennai) and authenticated from Siddha Centre Research Institute, 
Arumbakkam, Chennai-600106. 
CONTINUOUS SOXHLET EXTRACTION OR SOXHELATION:
 65 
        The preparation of various extracts of Amomum subulatum seeds was done in 
the Department of Pharmacology, Madras Medical College, Chennai-03 
The apparatus used for continuous hot percolation process was soxhlet apparatus 
which consist of three parts: 
1. Round bottom flask containing the boiling solvent 
2. Soxhlet extractor in which the drug to be extracted is packed. It has a side tube 
which carries the vapours of the solvent from the flask to be condenser and a siphon 
tube which siphons over the extract from soxhlet extractor to the flask. 
3. A condenser in which the vapour of the solvent are condensed to solvent 
PROCEDURE:   
The finely divided powder of the Amomum subulatum was placed inside a 
thimble made from thick filter paper, which was loaded into the main chamber of the 
soxhlet extractor .The soxhlet extractor was placed onto a flask containing the 
extraction solvent (methanol, petroleum ether).soxhlet was then equipped with a 
condenser with an inlet and outlet .The fluid was heated to reflux. The vapour travels 
up the distillation arm and floods into the chamber housing the thimble of solid 
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material. The condenser ensures that any vapour that cools drips back down into the 
chamber housing the solid material. The chamber containing the powder slowly fills 
with warm solvent. Some of the desired compound will then dissolve in the warm 
solvent. When the soxhlet chamber is almost full, the chamber is automatically 
emptied by a siphon side arm, with the solvent running back down to the distillation 
flask. This cycle was allowed to repeat many times, over 5-6 hours for 4 days. During 
each cycle, a portion of the non –volatile component dissolves in the solvent. After 
many cycles the desired compound is concentrated in the distillation flask. After 
extraction the solvent is removed, typically by means of a rotary evaporator, yielding 
the extracted compound. The non –soluble portion of the extracted solid remains in 
the thimble, and was discarded. 
         The seeds of amomum subulatum were dried, powdered and subjected to 
successive extraction by soxhlet apparatus using methanol and pet. Ether as solvents. 
After the extraction the products were concentrated by using rotary evaporator by 
removing solvents. Then the extracts were dried and stored in a suitable air tight 
container. The extracts can used whenever they required.  
Practical yield of Methanol extracts- 3.2%w/w 
Practical yield of Petroleum ether extracts- 2.3%w/w 
ACUTE TOXICITY STUDY:
 49 
        Acute toxicity studies have been already performed and it was found to be safe 
upto 2000mg/kg p.o. Hence, the doses selected for this study were 200 mg/kg p.o. 
5.2 PRELIMINARY PHYTOCHEMICAL SCREENING
66, 67
 
 
    Phytochemical evaluation is used to determine the nature of Phytoconstituents 
present in the plant by using suitable chemical tests. It is essential to study the 
pharmacological activities of the plant. The chemical tests for various 
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Phytoconstituents in the extracts of Amomum subulatum were carried out as described 
below and the results were recorded. 
1] DETECTION OF ALKALOIDS 
Dragendorff’s reagent: 
The substance was dissolved in 5ml of distilled water, to this 5ml of 2M Hcl 
was added until an acid reactions occurs, then 1ml of Dragendorff’s reagent was 
added and examined for an immediate formation of an orange red precipitate. 
Mayer’s reagent: 
The substance was mixed with little amount of dilute hydrochloric acid and 
Mayer’s reagent and examined for the formation of white precipitate. 
Wagner’s reagent: 
The test solution was mixed with Wagner’s reagent and examined for the 
formation of reddish brown precipitate. 
2] DETECTION OF CARBOHYDRATES 
Molisch’s test :  
 Filtrate was treated with 2drops of Molisch’s reagent in a test tube and 
2ml of Conc. Sulphuric acid was added carefully along the sides of the test tube. 
Formation of a violet ring at the junction indicates the presence of carbohydrates 
3] DETECTION OF GLYCOSIDES 
Borntrager’s test:  
A small amount of extract was hydrolysed with hydrochloric acid for few 
hours on a waterbath and the hydrolysate was extracted with benzene. The benzene 
layer was treated with dilute solution and observed for formation of reddish pink 
color. 
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Legal’s Test 
 The extract was dissolved in pyridine and was made alkaline with few 
drops of 10% sodium hydroxide and freshly prepared sodium nitroprusside was added 
and observed for the formation of blue color. 
4] DETECTION OF SAPONINS 
Foam test 
 1 ml of sample was taken, to that 2 ml of water was added .The suspension 
was shaken in a graduated cylinder for 15 minutes. Formation of layer of foam 
indicates the presence of saponins. 
5] DETECTION OF PHYTOSTEROLS   
Liebermann-Burchard’s Test 
 1 mg of the extract was dissolved in few drops of chloroform, 3 ml of 
acedic anhydride and 3 ml of glacial acedic acid. It is warmed and cooled under tap 
water and drops of concentrated sulphuric acid were added along the side of the test 
tube. The formation of bluish green colour indicates the presence of steroids. 
6] DETECTION OF PHENOLIC ACIDS AND TANNINS  
Ferric chloride Test 
 1ml of sample was taken, to that few drops of 0.1 % ferric chloride was 
added and allowed to stand for few minutes’ formation of Brownish green or blue 
black coloration indicates the presence of tannins. 
 1ml of sample was taken; to that 5ml of distilled water and few drops of 
neutral 5% ferric chloride solution was added. Formation of A dark green colour 
indicates the presence of phenol. 
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7] DETECTION OF PROTEINS AND AMINO ACIDS  
Ninhydrin Test 
 To the extract 0.25% of Ninhydrin reagent was added and boiled for few 
minutes. Formation of blue colour indicates the presence of amino acid. 
Biuret Test:  
 The extracts were treated with 1ml of 10% Sodium hydroxide solution 
and heated. To this a drop of 0.7% of copper sulphate solution was added. Formation 
of purplish violet colour indicates the presence of proteins. 
8] DETECTION OF FLAVONOIDS 
Shinoda Test  
 To 1 ml of sample, concentrated hydrochloric acid and magnesium chloride 
was added. Appearance of tomato red colour after few minutes indicates the presence 
of flavonoids. 
9] TEST FOR TERPENOIDS: 
Noller’s Test 
 The extracts were warmed with tin and thionly chloride. Pink colouration 
indicates the presence of terpenoids. 
10] DETECTION OF MUCILAGE 
 The extract is treated with aqueous potassium hydroxide; swelling 
indicates the presence of mucilage. 
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5.3 PHARMACOLOGICAL INVESTIGATION 
1) In-vitro antioxidant activity 
2) In-vivo sedative and antianxiety activity 
ANTIOXIDANT  
         Antioxidant is any substance that, when present at low concentration 
compared with those of an oxidizing substrate, significantly prevents or delays the 
oxidation of that substrate. Neutralizes free radicals and prevents cell damage that 
may lead to cancer. Any nutrient or chemicals that react with and neutralize free 
radicals to prevent oxidative damage to cells (e.g., oxidation of lipid membranes, 
DNA damage). A good biological antioxidant is able to accept an unpaired electron to 
form a free radical intermediate with a relatively long half-life in the normal 
biological environment. There is a complex intracellular enzymatic antioxidant 
system, including superoxide dismutase, catalase and enzyme of the glutathione 
peroxidase family. Nonenzymatic antioxidant includes arginine, vitamins A, C, E, B 
carotene, glutathione, polyphenols and minerals (selenium and zinc).
69 
 
5.3.1 IN-VITRO ANTIOXIDANT ACTIVITY 
 Oxidative stress is an imbalance between cellular production of reactive 
oxygen species and the counteracting antioxidant mechanisms. The brain with its high 
oxygen consumption and a lipid-rich environment is considered highly susceptible to 
oxidative stress or redox imbalances. Therefore, the fact that oxidative stress is 
implicated in several mental disorders including depression, anxiety disorders, 
schizophrenia and bipolar disorder, is not surprising.
70 
Some of the studies suggest 
that oxidative stress causes anxiety-related behaviors but do not explain the 
neurobiological pathways underlying the effect of oxidative stress on anxiety 
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symptoms. Some articles showed the use of antioxidant in the prevention or reduction 
of high anxiety.
71
 This may be due to the reason that GABA receptors activities are 
enhanced by antioxidants.
72-75
 the benzodiazepines act by binding to GABA receptor 
which is used as both sedative and anti anxiety drug predominantly by patients. 
Anti-oxidants like poly phenols and flavonoids are therefore very helpful in 
reduction of stress factors and free radical formation which inhibits GABA binding 
activity. It has become evident that flavonoids are able to exert enhancement ofGABA 
binding activity even at low concentration.
68 
 Based on this assumption between the anti-oxidant and the anxiety disorder, 
the antioxidant activity was conducted for all the extracts using the Nitric oxide 
radical scavenging activity.    
In vitro antioxidant activity was done for the two extracts (methanol and petroleum 
ether) using nitric oxide scavenging activity. 
 
 NITRIC OXIDE RADICAL SCAVENGING ACTIVITY: 
       Sodium nitroprusside (SNP) was measured according to the method of 
Marcocci et al. (1994). Briefly, the reaction mixture (5.0 ml) containing SNP (5 mM) 
in phosphate buffered saline (pH 7.3), with or without the plant extract at different 
concentrations, was incubated at 25˚C for two hours.The NO. radical thus generated 
interacted with oxygen to produce the nitrite ion (NO. ) which was assayed at 30 min 
intervals by mixing 1.0 ml of incubation mixture with an equal amount of Griess 
reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% 
naphthylethylenediaminedihydrochloride).
[76]
 The absorbance of the chromophore 
(purple azo dye) formed during the diazotisation of nitrite ions with sulphanilamide 
and subsequent coupling with naphthylethylenediamine dihydrochloride was 
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measured at 546 nm. A control was taken without test compound or standard. 
Ascorbic acid was taken as a reference antioxidant. All the tests were performed in 
triplicate and the results averaged. The percentage inhibition of nitric oxide generated 
was measured by comparing the absorbance values of control and test samples using 
following formula. 
% Radical scavenging activity = [(Abs) control – (Abs) sample / (Abs) control)] ×100 
Where, (Abs) control is the absorbance of the control, and (Abs) sample is the 
absorbance of the test compound. The IC50 values (concentration of sample required 
to scavenge 50% of free radicals) were calculated from the regression equation, 
prepared from the concentration of the samples and percentage inhibition of free 
radicals.
77-79 
 
5.3.2 IN-VIVO SEDATIVE AND ANTIANXIETY ACTIVITY 
       I  Elevated plus maze in mice were used to evaluate antianxiety activity 
       II Actophotometer/open field was used to evaluate spontaneous locomotor 
activity 
I EVALUATION OF ANTIANXIETY ACTIVITY IN MICE 
1) Elevated plus-maze in mice: 
21, 62, 80, 81, 83 
   Swiss albino mice divided into 4 groups each group containing 6 animals. The 
entire animals were freely accessible to water and food.
 
 
Drug administration: 
 Normal saline as vehicle, diazepam as standard and the test compound were 
administered orally using orogastric tube, 60 minutes prior to introduction of mice 
into elevated plus-maze.  
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Group I: control group received normal saline, 10ml/kg per orally 
Group II: standard group received diazepam, in the dose of 3mg/kg per orally 
Group III: methanol extracts of Amomum subulatum seeds, in the dose of 200mg/kg 
per orally 
Group IV: pet. Ether extracts of Amomum subulatum seeds, in the dose of 200mg/kg 
per orally 
      The antianxiety activity of plant extracts was evaluated using the Elevated 
plus-maze test. The apparatus consists of two open arms of 18×4cms and two closed 
arms of 18.4×4×16cms having an open roof, with the plus-maze elevated to 25cms 
from the floor. Sixty minutes after oral administration of the test and standard drugs, 
each animal was placed at the center of the maze facing the open arm of the maze. 
During the 5 min test period, the number of entries and the time spent in open and 
enclosed arms were recorded. An entry into an arm was defined as the point when the 
animal places all four paws onto the arm. Following each trial using 70% ethanol 
thoroughly clean the apparatus. The behavior of the animal scored by using hand 
operated counters and stop watches. The procedure was carried out in a sound 
attenuated room; observations were made from an adjacent corner. 
The percentage of time spent and entries in the open arm were considered as index. 
1. Percentage of open arm entries= (number of open arm entries /number of open arm 
entries+ number of closed arm entries) ×100 
2. Percentage time spent in open arms= (time spent in open arm/time spent in open 
arm+ time spent in closed arm) ×100 
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                                     Fig.4. Elevated plus maze apparatus 
 
II EVALUATION OF LOCOMOTOR ACTIVITY IN MICE 
   Two well established models were used to evaluate the locomotor activity 
1. Actophotometer  
2. Open field test in mice 
1) Actophotometer: 
21, 62 
      Albino mice were divided into four groups each containing 6 animals. All the 
animals were freely accessible to food and water. 
  Drug administration: 
      Normal saline as vehicle, diazepam as standard and the test compound were 
administered orally using orogastric tubes 
Group I: control group received normal saline, 10mg/kg per oral 
Group II: standard group received diazepam, in the dose of 3mg/kg per oral 
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Group III: methanol extracts of amomum subulatum seeds, in the dose of 200mg/kg 
per oral 
Group IV: pet. Ether extracts of amomum subulatum seeds, in the dose of 200mg/kg 
per oral 
          To evaluate locomotor activity, each mice was placed into an actophotometer 
and its score of locomotor were measured for a period of 10 minutes. 
        The locomotor activity was measured using a digital actophotometer which 
operates on photoelectric cells which are connected in circuit with a counter. When 
the beam of light falling on the photocell is cut off by the animal, a count is recorded 
and displayed digitally. Mice were administered with control, standard and test 
compounds 1 hour prior to the experiment and the response taken for 30 minutes once 
for 1 hour and were tested for activity score for 10 minutes. Decreased activity score 
was taken an index of CNS depression. 
 
                                                 Fig.5.Actophotometer 
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2) Open field method 
81, 82 
        Albino mice were divided into 4 groups each containing 6 animals. All the 
animals were freely accessible to food and water. 
Drug administration 
        Normal saline as vehicle, diazepam as standard and the test compound were 
administered orally using orogastric tubes. 
Group I: control group received normal saline, 10mg/kg per oral 
Group II: standard group received diazepam, in the dose of 3mg/kg per oral 
Group III: methanol extracts of amomum subulatum seeds, in the dose of 200mg/kg 
per oral 
Group IV: pet. Ether extracts of amomum subulatum seeds, in the dose of 200mg/kg 
per oral 
          The experiment was carried out to determine depressive action of the test 
drugs on CNS in mice. Open field apparatus is taken for the experiment which 
consists of 16 squares, each side of square having the length of 24 cm and height 17 
cm. the total length is 97 cm on each side of the apparatus. The number of squares 
visited by the animals was counted for 10 min at 30 and 60 min after oral 
administration of the test and standard drugs. 
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                              Fig.6. open field apparatus 
 
 
5.4 STATISTICAL ANALYSIS
84 
       All the values were expressed as mean ± SEM. The data was statistically 
analyzed by one way ANOVA followed by Dunnet’s test. One way analysis of 
variance (ANOVA) was used to correlate the statistical difference between the 
variables. P<0.05 was considered to be significant. Statistical analysis was done using 
graphpad prism 7 software. 
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                          6. RESULTS AND DISCUSSION 
6.1 PHYTOCHEMICAL ANALYSIS 
              The phytochemical analysis of various extracts was performed and presence 
of flavonoids, phytosterol, carbohydrate, terpenoids, Proteins and amino acids were 
significant. 
Table No. 2: Qualitative Phytochemical analysis 
S.No Tests 
Methanolic 
extracts 
Petroleum ether 
extracts 
1 Alkaloids 
 
+ _ 
2 Carbohydrates  
 
+ 
 
+ 
3 Glycosides  + _ 
4 Saponins  _ _ 
5 Phytosterols 
 
+ + 
6 Tannins and phenolic compound 
 
+ _ 
7 Proteins & amino acids  
 
+ 
+ 
8 Flavonoids 
 
+ 
+ 
9 Terpenoids 
 
+ 
+ 
10 Mucilage _ + 
           Note: + indicates presence, - indicates absence 
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6.2 INVITRO ANTIOXIDANT ACTIVITY 
Nitric oxide radical scavenging activity 
Antioxidant activity was evaluated by using nitric oxide radical scavenging 
activity method. In this study two extracts are used namely methanol and petroleum 
ether the % inhibition release of nitric oxide is the parameter considered as their 
antioxidant activity. 
The % inhibition of methanol, petroleum ether and standard ascorbic acid 
values are mentioned in table 3 and Fig. 7&8. the extracts was able to neutralize nitric 
oxide in a concentration dependent manner at a concentration range of 200-
1000µg/ml and IC50 (µg/ml) value has been calculated and was found to be 213µg/ml 
for ascorbic acid, whereas methanol and petroleum ether extracts showed the IC50 –
value (µg/ml) of 238.9 and 237 respectively. From the studies the methanol and 
petroleum ether extracts have significant antioxidant activity in comparison to the 
standard (ascorbic acid). 
Recent studies show that antioxidants are responsible for antianxiety and 
sedative activity. Hence the extracts are subjected for antioxidant activity and it is 
found out that all the extracts show antioxidant activity to a certain extent compared 
to the standard. There forth all the extracts can be further used for in vivo studies. 
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Table 3: Nitric oxide radical scavenging activity of ascorbic acid, methanol and 
petroleum ether extracts 
 
S. 
No. 
 
 
 
Concentration(µg/ml) 
 
% of scavenging of NO 
 
Ascorbic 
acid 
Methanol   
extract 
Petroleum ether 
extract 
 
1. 
 
200 
 
49.528 
 
48.58 
 
46.16 
 
2. 
 
400 
 
69.974 
 
57.33 
 
65.41 
 
3. 
 
600 
 
77.857 
 
58.14 
 
70.12 
 
4. 
 
800 
 
93.361 
 
62.58 
 
85.46 
 
5. 
 
1000 
 
96.266 
 
72.27 
 
91.11 
 
IC50 (µg/ml) 
 
213 
 
238.9 
 
237 
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                       Fig.7. Comparative NO scavenging activity with Standard  
 
 
 
                  Fig.8. Comparative NO scavenging activity with Standard  
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6.3 INVIVO STUDIES 
I ANTIANXIETY ACTIVITY IN MICE USING ELEVATED PLUS MAZE 
METHOD 
The elevated plus maze test is most popular test for evaluation of anxiolytic 
compounds. The elevated plus maze is highly sensitive to the influence of both 
anxiolytic and anxiogenic drug acting at the GABAA benzodiazepine complex. The 
EPM test is used to evaluate the psychomotor performance and emotional aspects of 
mice. EPM is considered as one of the well-established model for unconditioned 
anxiety to detect anxiolytic/anxiogenic like activity by investigating aspects of 
physiological and pharmacological behavior. In EPM, mice will normally prefer to 
spend much of their allotted time in enclosed arms. This preference appears to reflect 
an aversion towards open arms that is generated by the fears of the open spaces. In the 
EPM test increased number of entries and time spent into the open arm are taken as 
the index/reliable indicators of decreased anxiety or indicating the anxiolytic-like 
activity of a compound.
85-87 
The percentage open arms entry with control group was 12.43±1.14 and the 
percentage time spent in open arms was 7.6±0.67 seconds. 
With diazepam 3mgs/kg in group II, the percentage open arms entries was 66.81±0.58 
and the percentage time spent in open arm was 69.93±0.41 seconds when compared to 
control groups. 
With test group III i.e. methanolic extract of Amomum subulatum seeds 200mg/kg, the 
percentage of open arm entry was 40.55±0.52 and percentage time spent in open arm 
was 46.73±0.63 seconds. 
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With test group IV i.e. petroleum ether extract of Amomum subulatum seeds 
200mg/kg, the percentage of open arm entry was 50.28±0.9 and percentage time spent 
in open arm was 56.50±0.39 seconds. 
The result with methanol and petroleum ether extracts of Amomum subulatum seeds in 
the dose of 200mg/kg was highly significant when compared to control as shown in 
table 4 and Fig.9&10 
Table 4: Effect of methanol and petroleum ether extracts of Amomum subulatum 
seeds in elevated plus maze 
 
S.
No 
 
Treatment group 
 
% open arm entries 
 
% time spent 
in open arm 
 
1 
 
Control 
 
12.43±1.14 
 
7.6±0.67 
 
2 
 
Diazepam 3mg/kg 
 
66.81±0.58
*** 
 
69.93±0.41
*** 
 
3 
 
MEASS in the dose of 
200mg/kg 
 
40.55±0.52
***
 
 
 
46.73±0.63
*** 
 
4 
 
PEASS in the dose of 200mg/kg 
 
50.28±0.9
*** 
 
56.50±0.39
***
 
 
All values are expressed as Mean±SEM(n=6). One way ANOVA followed by 
Dunnet’s test.  *** P˂0.001 when compared to control. 
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MEASS- methanol extracts of Amomum subulatum seeds 
PEASS- Petroleum ether extracts of Amomum subulatum seeds 
In the present study, mice treated with methanol and petroleum ether extracts 
of Amomum subulatum seeds at the doses of 200mg/kg produced significant 
(P˂0.001) anxiolytic effects. In the EPM test when compared to control as evidenced 
by increased percentages of both open arm entries and time spent in open arms when 
compared to control group of animals. 
 
                Fig.9.percentage open arm entries in elevated plus maze 
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              Fig.10.percentage time spent in open arm in elevated plus maze 
 
II SPONTANEOUS LOCOMOTOR ACTIVITY 
Spontaneous locomotor activity is considered as an index of alertness and can 
be helpful to confirm the general depressive activity of any drug. The decrease in 
motor activity gives an indication of the level of depression of CNS.
88 
Since, an anxiolytic also produces sedation and hypnosis; these activities were 
evaluated with spontaneous locomotor activity in Actophotometer and open field test. 
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1) Actophotometer 
Actophotometer registers the number of times photo beams of light was 
broken as the mice moved around inside the cage. Each mice was placed in the centre 
of the metal cage of actophotometer and its ambulatory activity was measured for 10 
minutes.
89 
Locomotor activity is evaluated by using Actophotometer. The spontaneous 
locomotor activity made by a mouse was noted in control, standard and test group 
before and 30 and 60 min after the administration of control, standard and test drugs. 
The average number of counts at before and 30 and 60 min after the administration of 
control group of mice was 196.17±2.6, 190.67±2.38 and 189.83±2.5 respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
standard group of mice was 199.17±3.0, 117.5±2.2 and 80.5±2.6 respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
test group (methanol extract) of mice was 192.16±3.0, 162.17±1.6 and 135.83±2.4 
respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
test group (pet. Ether extract) of mice was 181.67±2.49, 153±2.9 and 119.3±1.8 
respectively. 
In actophotometer test, number of cut off (crossing) decreases in test groups compared 
to control group .The results were shown in table 5 and Fig.11&12 
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Table 5: Locomotor activity of mice in actophotometer 
 
S.No 
 
Treatment group 
Before drug 
administration 
 
after 30 min 
 
after 60 min 
 
1 
 
Control 
 
196.17±2.6 
 
190.67±2.38 
 
189.83±2.5 
 
2 
 
Diazepam 3mg/kg 
 
199.17±3.03 
 
117.5±2.24
*** 
 
80.5±2.6
*** 
 
3 
 
MEASS in the dose 
of 200mg/kg 
 
192.16±3.07 
 
162.17±1.58
* 
 
135.83±2.4
*** 
 
4 
 
PEASS in the dose 
of 200mg/kg 
 
181.67±2.49 
 
153±2.9
** 
 
119.3±1.8
*** 
All values are expressed as Mean±SEM (n=6). One way ANOVA followed by 
Dunnet’s test. *P<0.05, **P<0.01 and *** P˂0.001 when compared to control. 
MEASS- methanol extracts of Amomum subulatum seeds 
PEASS- Petroleum ether extracts of Amomum subulatum seeds 
In the present study, mice treated with methanol and petroleum ether extracts 
of Amomum subulatum seeds at the dose of 200mg/kg showed A statistically 
significant (P<0.001) reduction in spontaneous locomotor activity in actophotometer 
after 60 minutes of administration of standard and test compounds were noted in 
comparison with control group of animals that signifies sedative activity. 
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     Fig.11.Locomotor activity of mice in actophotometer (After 30 minutes) 
 
 
        Fig.12.Locomotor activity of mice in actophotometer (After 60 minutes) 
C
on
tr
ol
D
ia
ze
pa
m
(3
m
g/
kg
)

M
E
A
S
S
(2
00
m
g/
kg
)
PE
A
S
S
(2
00
M
g/
kg
)
0
20
40
60
80
100
120
140
160
180
200
220
240
                      locomotor activity of mice in actophotometer
                                                                                                             After 30 minutes
N
u
m
b
e
r 
o
f 
 c
ro
s
s
in
g
***
* **
Co
nt
ro
l
Di
az
ep
am
(3
m
g/
kg
)

M
EA
SS
(2
00
m
g/
kg
)
PE
AS
S(
20
0M
g/
kg
)
0
20
40
60
80
100
120
140
160
180
200
220
240
                      locomotor activity of mice in actophotometer
                                                                                                     After 60 minutes
N
u
m
b
er
 o
f 
 c
ro
ss
in
g
***
***
***
                                                                                                 Result & Discussion 
 
Institute of Pharmacology, MMC. Page 77 
 
 
2) Open field method 
In open field apparatus consists of a square open area which is divided by lines 
into 16 equal squares. The locomotor activity is determined by manually counting the 
number of lines crossed by the animal during a fixed time of 10 minutes.
 
Locomotor activity is evaluated by using open field method. The spontaneous 
locomotor activity made by a mouse was noted in control, standard and test group 
before and 30 and 60 min after the administration of control, standard and test drugs. 
The average number of counts at before and 30 and 60 min after the administration of 
control group of mice was 165.83±1.5, 170±1.28 and 164.7±1.26 respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
standard group of mice was 159±1.16, 99.33±2.2 and 72.67±1.22 respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
test group (methanol extract) of mice was 153.17±2.5, 136.17±2.03 and 101.83±1.6 
respectively. 
The average number of counts at before and 30 and 60 min after the administration of 
test group (pet. Ether extract) of mice was 156.5±2.9, 117.67±2.8 and 98.5±2.0 
respectively. 
In the open field test, the number of squares traveled by the mice was 
suppressed significantly in the test group at dose of 200mg/kg. The CNS depressant 
activity obtained for the extracts was statistically significant and the results were 
shown in table 6 and Fig.13&14 
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Table 6: Locomotor activity of mice in open field 
 
S.
No 
 
Treatment group 
 
Before drug 
administration 
 
after 30 min 
 
after 60 min 
 
1. 
 
Control 
 
165.83±1.5 
 
170±1.28 
 
164.7±1.26 
 
2. 
 
Diazepam 3mg/kg 
 
159±1.16 
 
99.33±2.24
*** 
 
72.67±1.22
*** 
 
3. 
 
MEASS in the dose of 
200mg/kg 
 
153.17±2.5 
 
136.17±2.03
** 
 
101.83±1.6
*** 
 
4. 
 
PEASS in the dose of 
200mg/kg 
 
156.5±2.9 
 
117.67±2.8
** 
 
98.5±2.0
*** 
All values are expressed as Mean±SEM(n=6). One way ANOVA followed by 
Dunnet’s test. **P<0.01, *** P˂0.001 when compared to control. 
MEASS- methanol extracts of Amomum subulatum 
PEASS- Petroleum ether extracts of Amomum subulatum seeds 
In the present study, mice treated with methanol and petroleum ether extracts of 
Amomum subulatum seeds at the dose of 200mg/kg showed A statistically significant 
(P<0.001) reduction in spontaneous locomotor activity in open field after 60 minutes 
of administration of standard and test compounds were noted in comparison with 
control group of animals that signifies sedative activity. 
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           Fig.13.locomotor activity of mice in open field (After 30 minutes) 
 
 
        Fig.14.locomotor activity of mice in open field (After 60 minutes) 
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Despite intensive efforts to develop novel psychiatric drugs for anxiety and 
depression disorders over the past two decades, all drugs have so far failed to 
minimize side effects. In this respect, herbal medicines could be an attractive 
candidate as the therapeutic strategies for this conditions.
90
 A major role for plant-
derived compounds based on the reported immunomodulatory effects has emerged in 
recent times and has led to the rigorous scientific examination to determine efficacy 
and safety.
81 
      The result of actophotometer and open field tests showed that the studied plant 
decreased the frequency as well as the bountifulness of movements. Since the level of 
excitability of the CNS is measured by locomotor activity, this reduction in 
spontaneous motor activity that could be considered as the sedative effect of the plant 
extracts. 
      The above result showed that crude methanolic and petroleum ether extracts of 
Amomum subulatum plant had strong sedative activity that principally mediated in the 
CNS by the GABAA receptor complex. Benzodiazepines and barbiturate drug produce 
sedative-hypnotic effect at a certain dose due to their interaction with GABAA 
receptors which enhances the GABAergic transmission. It potentiates GABA activity, 
entering chloride into the neuron by prolonging the duration of chloride channel 
opening. All of these molecular action lead to decrease of neuronal activity that 
support the following reference substances which possess sedative action.
81 
 However, the anxiolytic activity of the methanolic and petroleum ether 
extracts of Amomum subulatum plant was measured by using EPM suggested when 
the test drug increases open arms entries without altering the total number of arm 
entries. Diazepam has been used as a standard anxiolytic and also frequently 
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employed in behavioral pharmacology as a reference compound of potentially 
anxiolytic-acting substances. But the fractions of plant extract at 200 mg/kg body 
weight in mice showed significant increase in the percentage of entries into open arms 
and time spent in the open arms of the maze. 
      Analyzing the results of present study, it can be inferred that the crude 
methanolic and petroleum ether extracts of Amomum subulatum plant seeds at the 
dose of 200mg/kg possess strong sedative and anxiolytic activity. Therefore, this 
extract could be considered for the treatment of anxiety and related neuropsychiatric 
disorders by conducting further pharmacological studies and mechanism of sedative 
and anxiolytic action, as well as to identify the active compound(s) responsible for 
this bioactivity in the animal model 
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                                     CONCLUSION 
Preliminary phytochemical investigation was done for the various extracts of 
Amomum subulatum seeds. It was found to contain flavonoids, phytosterol, 
carbohydrate, terpenoids and Protein& amino acids, etc… 
    The present study shows that the methanol and petroleum ether extracts of 
Amomum subulatum seeds have higher antioxidant activity which was determined 
using the method (Nitric oxide radical scavenging activity). 
         The study shows that extracts of Amomum subulatum seeds at the dose of 
200mg/kg has significant antianxiety and sedative activity. 
         The study also shows that the antianxiety and sedative activity of various 
extracts of Amomum subulatum seeds at the dose of 200mg/kg is less efficacious 
when compared to the standard drug diazepam at the dose of 3mg/kg. 
         The results from the experiments confirmed that the methanolic and petroleum 
ether extract from Amomum subulatum seeds posses a strong sedative and anxiolytic 
potential. However, the further studies in other models and extensive phytochemical 
analysis are necessary to identify the exact chemical compound and its possible 
mechanism of action underlying the anxiolytic and sedative effect of Amomum 
subulatum seeds. 
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                                      SUMMARY 
Anxiety related disorders are the most common mental illness and a major 
cause of disability in the world. Mental disorders have been found to be common, 
with over a one third of people in most countries reporting them with sufficient 
criteria to be diagnosed at one point in their life.
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       Insomnia is a frequent problem that affects people of all the ages around the 
world. It is a prevalent and potentially serious condition that adversely affects the 
diurnal functioning, health status and life quality of people of all of age. Stress, 
anxiety and depression could trigger insomnia. 
       Despite a phenomenal development of modern drug industry, medicinal plants 
still constitute an important part of pharmacopoeias in both the developed and 
developing countries. These plants are important elements of traditional medicine and 
can be developed as potential drug after scientific validation. However, many of these 
traditionally used plants have not yet been studied scientifically.
91 
       Amomum subulatum is an important medicinal plant of family zingiberaceae 
commonly known as black cardamom. A number of pharmacological activities have 
been reported such as antiulcer, antibacterial, antifungal, hepatoprotective, 
antidiabetic, hypolipidaemic activity, anti-inflammatory and analgesic activity.
92 
The results of Preliminary phytochemical investigation shown the presence of 
various phytochemical constituents like flavonoids, phytosterol, carbohydrate, terpenoids 
and Protein& amino acids, etc... 
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       In vitro studies in nitric oxide radical scavenging assay was carried out to 
select the most active extract. Based on the results both methanol and petroleum ether 
extract of seeds were selected for further in vivo studies. 
       In-vivo study was done using elevated plus maze test for the evaluation of 
anti-anxiety activity of the extracts. Anxious mice mostly preferred the closed arm, 
after administration of the extracts the animal spent more time in open arm due to the 
anti anxiety activity of the extracts.  
       Further two well established animal models, actophotometer and open field 
methods were used to evaluate locomotor activity of mice. The animal treated with 
methanol and petroleum ether extracts showed decrease in locomotor activity. 
       The result of the study showed that extracts Amomum subulatum seeds at the 
dose of 200mg/kg has antianxiety and sedative activity that was statistically 
significant. 
       Further studies need to be done to elucidate specific mechanism and active 
principles responsible for its sedative and antianxiety activity. 
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